Denali Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon. Thanks, everyone, for joining. Salveen Richter, biotechnology analyst at Goldman Sachs, and really pleased to have the Denali team with us. So with us, we have Ryan Watts, who's the CEO, Co-Founder and President; and Alexander Schuth, who is the COO and CFO and Co-Founder as well. Thank you both for joining us.
Questions & Answers
To start here, maybe just an outlook question on the company. You've made steady progress with your pipeline here, notably with the positive data that we've seen from the blood-brain barrier with that first data in Hunter's syndrome. And then we've also seen Biogen opt-in recently to the ATV data program. So as we look to the second half of the year, what do you see as the most important steps to further advance these different verticals and programs? And where should investors be most focused?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
